 Photo courtesy of Novartis AG |
Last year (our 2005 edition), Pfizer was 47% ahead of its closest competitor in drug revenues ($46 billion to $31 billion), but that margin was shaved to 30% in 2005 as Pfizer sales dropped 4%. The company remains at #1 in our Top 20 Pharmaceutical rankings, with a $10 billion buffer between it and neck-and-neck competitors Sanofi-Aventis and GlaxoSmithKline, but for how long?
Roche posted the biggest dollar gains in 2005 revenues, up $2.8 billion (20%), thanks to a major contribution from Tamiflu (up $987 million in 2005).
At the lower end of our ranks, recent mergers in Japan have brought Astellas and Daiichi-Sankyo into the Top 20. Bayer’s acquisition of Schering AG will lead to another major jump next year, and more pressure placed on mid-tier firms.
Come to think of it, if a few of these “national champion” mergers come through—think GSK/AstraZeneca, and the long-anticipated Novartis/Roche combo—we could see a whole new lineup. . .
—Gil Y. Roth
Editor
ContributorsEditor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
Top 20 Pharmaceutical Companies |
||
based on 2005 pharma revenues |
||
| 1 | Pfizer | $44,284 |
| 2 | Sanofi-Aventis | $34,013 |
| 3 | GlaxoSmithKline | $33,976 |
| 4 | AstraZeneca | $23,950 |
| 5 | Johnson & Johnson |
$22,322 |
| 6 | Merck & Co. |
$21,874 |
| 7 | Novartis | $20,262 |
| 8 | Roche | $16,613 |
| 9 | Bristol-Myers Squibb |
$15,254 |
| 10 | Wyeth | $14,280 |
| 11 | Eli Lilly & Co. |
$13,781 |
| 12 | Abbott Laboratories |
$13,300 |
| 13 | Boehringer-Ingelheim | $9,025 |
| 14 | Takeda Pharmaceutical |
$9,019 |
| 15 | Schering-Plough | $8,759 |
| 16 | Astellas Pharma |
$7,503 |
| 17 | Daiichi-Sankyo | $6,944 |
| 18 | Novo Nordisk |
$5,643 |
| 19 | Eisai | $5,131 |
| 20 | Bayer AG |
$5,065 |
|
|
||
